Literature DB >> 2370288

Use of serum substitutes for the growth of four cell lines commonly used for virus isolation.

C A Gleaves1, D H Rice, J D Meyers.   

Abstract

Four serum extenders (Opti-MEM I, BioRich, Excyte I and Excyte III) and two serum substitutes (Omni Serum and Serum Plus) were evaluated for the reduction or replacement of FBS for the growth and maintenance of four representative cell lines used for virus isolation. MRC-5, human fetal foreskin fibroblast (HF), A549 and Hep-2 cells were seeded into culture flasks containing MEM with 10% FBS or with the serum extenders or substitutes and subcultured into 16 x 125 mm glass tubes and 1-dram shell vials. Only cells cultured with Opti-MEM I and Omni Serum grew consistently in tubes and vials and these reagents were compared to FBS for viral isolation and detection. Laboratory stocks of CMV, HSV, VZV, adenovirus (Ad) and RSV were tested. In HF and MRC-5 cells, CMV was isolated in cells cultured in either Opti-MEM I or Omni Serum before CPE appeared in cultures containing FBS. Ad and VZV CPE were observed first in HF and MRC-5 cells containing Omni Serum. HSV CPE was seen at the same time in HF and MRC-5 cells with all 3 media. HSV and Ad CPE in A549 cells were also seen at the same time in all 3 media. RSV and Ad CPE in Hep-2 cells were observed first in FBS containing media. Both Opti-MEM I and Omni Serum performed well as substitutes for FBS for growth of stock viruses without loss of cell sensitivity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2370288     DOI: 10.1016/0166-0934(90)90032-b

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  2 in total

1.  Fortified sera and their use in environmental virology.

Authors:  J L Hoyt; A B Margolin
Journal:  Appl Environ Microbiol       Date:  2000-05       Impact factor: 4.792

2.  Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies.

Authors:  Rodrigo Martino; Rocío Parody Porras; Nuria Rabella; John V Williams; Elena Rámila; Nuria Margall; Rosa Labeaga; James E Crowe; Pedro Coll; Jorge Sierra
Journal:  Biol Blood Marrow Transplant       Date:  2005-10       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.